Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- BBB is an impediment in CNS drug development
- CNS drug development
- The evolving concept of the blood-brain barrier
- Neurovascular unit as an integrated concept
- Tight junctions form the 'physical' barrier
- The transport systems of the blood-brain barrier
- Strategies to deliver drugs into the brain (1)
- Strategies to deliver drugs into the brain (2)
- Strategies to deliver drugs into the brain (3)
- Routes for drug delivery across the BBB
- Transcellular lipophilic diffusion
- Inhibition of efflux pumps
- Paracellular hydrophilic diffusion
- Carrier-mediated transport
- Adsorptive endocytosis
- Receptor-mediated transcytosis
- The molecular 'Trojan horses' concept
- 'Trojan horses'
- HIR as a 'Trojan horse' for drug delivery to the brain
- 'Trojan horses' and nanocarriers
- Considerations in designing 'Trojan horses'
- Discovery and development of novel 'Trojan horses'
- Single domain antibodies
- Single-domain antibody phage display libraries
- Selection of the BBB - targeting sdAbs
- Brain-targeting single-domain antibodies
- Mechanisms of transport
- Linking molecules to FC5
- In vivo biodistribution of FC5
- Improving FC5 pharmacokinetics
- Brain accumulation of FC5 formulations
- Detection of FC5 in brain tissues
- Detection of FC5 by confocal microscopy (1)
- Detection of FC5 by confocal microscopy (2)
- Summary
- FC5-functionalized liposomes
- Delivery using FC5-functionalized liposomes (1)
- Delivery using FC5-functionalized liposomes (2)
- Tailoring BBB delivery strategies (1)
- Tailoring BBB delivery strategies (2)
Topics Covered
- Restrictive nature of the blood-brain barrier
- Non-vascular routes for brain drug delivery
- Vascular routes for brain drug delivery
- Concept of Trojan horses
- Discovery of novel receptor-mediated transcytosis routes across the blood-brain barrier
- Principles of blood-brain barrier vector development in experimental models
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stanimirovic, D. (2008, March 1). The blood-brain barrier and CNS drug development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/GGED9050.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Danica Stanimirovic has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.